Hunton & Williams LLP has substantial experience representing international biotechnology companies from both a regulatory and intellectual property perspective. From a regulatory standpoint, the firm provides a broad range of focused legal and regulatory counseling to companies of all sizes. Hunton & Williams regulatory lawyers have diverse and complementary backgrounds that include experience and academic degrees in science, business, public policy and government relations. The firm serves clients by providing practical advice effectively and efficiently, by marshaling the appropriate resources to fulfill the client’s business objectives, whether those objectives involve navigating a complex regulatory path, negotiating a major transaction, developing a marketing strategy, responding to an enforcement action or litigating with a competitor. The firm also has significant knowledge in intellectual property matters specific to biotechnology companies, including patent preparation and prosecution, patent interferences, patent opinion work and litigation. Of the firm's more-than-90-member intellectual property section, approximately 15 lawyers devote a substantial part of their practice to biotech. Included in that group are several who have completed graduate-level work in the area. Members of the team have an impressive range of experience in the biotech industry, some with as much as 30 years.
- Educate delegates to the first meeting of the parties to the Biosafety Protocol, Kuala Lumpur, February 2004, on liability and redress.
- Advise major international food and non-food companies on regulatory requirements under EC law relating to the contained use, experimental release, marketing and labeling of genetically modified organisms (GMOs) and products derived from GMOs.
- Advise on premarketing authorization and labeling of novel foods under EC law.
- Analyze national laws in Denmark, Finland, Ireland, Norway, Portugal, Spain, Sweden, and the United Kingdom concerning the contained use, experimental release, marketing and labeling of GMOs, products derived from GMOs and "novel foods".
- Advise a major biotechnology company on liability and other issues under the Biosafety Protocol pursuant to the 1992 UN Biodiversity Convention.
- Analyze civil liability for damage caused by GMOs under the laws of continental European jurisdictions.
- Gary C. Messplay
- Lucas C. Bergkamp
- Robert M. Schulman